D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. [electronic resource]
- Molecular cancer therapeutics Jan 2007
- 193-202 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1535-7163
10.1158/1535-7163.MCT-06-0482 doi
Animals Antineoplastic Agents--pharmacology Apoptosis--drug effects Ataxia Telangiectasia Mutated Proteins Carcinoma, Renal Cell--pathology Cell Cycle Proteins--metabolism DNA Adducts--drug effects DNA Damage DNA-Binding Proteins--metabolism Drug Resistance, Neoplasm--drug effects Enzyme Activation--drug effects Flow Cytometry HT29 Cells HeLa Cells Heterocyclic Compounds, 3-Ring--pharmacology Humans Male Mice Mice, Nude Organoselenium Compounds--pharmacology Protein Kinase C--metabolism Protein Kinase C beta Protein Kinase C-alpha--metabolism Protein Serine-Threonine Kinases--metabolism Pyrroles--pharmacology Reactive Oxygen Species--metabolism S Phase--drug effects Signal Transduction--drug effects Tumor Suppressor Proteins--metabolism Xenograft Model Antitumor Assays